by Brandon Tudor | Mar 2, 2025 | Uncategorized
From the AJMC Journal 02/27/2025: “At 2 years, participants in the compensated MASH cirrhosis treatment arm of the MAESTRO-NAFLD-1 trial experienced a statistically significant 6.7 kPa reduction in liver stiffness from baseline.” Per the article by Rose...
by Brandon Tudor | Feb 26, 2025 | Uncategorized
“Our study…demonstrate[s] an increased risk of HF in MASLD patients and suggests individuals with MASLD and a high metabolic burden should be vigilant about the potential development of HF.”Conclusion from the 08 January 2025 study published in The...
by Brandon Tudor | Feb 14, 2025 | Uncategorized
We joined the AASLD, and will be at this event in Las Vegas in late February/early March of 2025, and I’d like to meet with attendees– please reach out to me (Brandon Tudor) on LinkedIn.When & Where Date: Thursday, February 27, 4:00 pm –...
by Brandon Tudor | Feb 12, 2025 | Uncategorized
From 02/11/2025: Study Finds 3 in 4 Overweight, Obese Adults Have Steatotic Liver Disease MASH As much as 75% of overweight and obese individuals have steatotic liver disease, according to results of a recent cross-sectional, observational study. In addition, the...
by Brandon Tudor | Feb 6, 2025 | Uncategorized
LiverRight will be at the American Association for the Study of Liver Diseases (AASLD) Emerging Topic Conference 2025 – “MASLD, MetALD and ALD: Challenges and Opportunities.”Date: Thursday, February 27, 4:00 pm – Saturday, March 1, 7:30 pm...
